FLT3 and acute lymphoblastic leukemia: The second most common FLT3 mutations are missense point mutations in the tyrosine kinase domain which occur in approximately 5–10% of AML, 2–5% of MDS and 1–3% of acute lymphocytic leukemia (ALL) cases [46,51,52].